Peer-reviewed/ Observational study/ People
- First study on cases from the ongoing outbreak of monkeypox in the UK looks at the clinical and demographic features of 54 patients with confirmed monkeypox infection who attended sexual health clinics in London.
- Researchers observed differences in the symptoms of these cases compared to previous monkeypox outbreaks, including the location of skin lesions and a lower prevalence of tiredness and fever, and call for a review of the current UKHSA case definitions.
- The analysis finds all 54 cases identified as men who have sex with men. A high proportion of cases had skin lesions in their anus or genital regions, suggesting transmission during close skin-to-skin contact, such as sexual activity.
- Authors call for additional resources to support sexual health and other specialist services in managing the current monkeypox outbreak.
The first study on cases in the current UK monkeypox outbreak reports important differences in patient’s symptoms to those observed in previous outbreaks elsewhere in the world. The study, published in The Lancet Infectious Diseases journal, looked at 54 patients who attended sexual health clinics in London, UK and were diagnosed with monkeypox during a 12 day period in May 2022.
The findings suggest that patients in this cohort had a higher prevalence of skin lesions in the genital and anal area and lower prevalence of tiredness and fever than in cases from previously studied outbreaks of monkeypox. Based on this study’s findings, the authors suggest current case definitions for ‘probable cases’ of monkeypox  should be reviewed to help identify cases.
The authors also predict that the high prevalence of genital skin lesions in patients and the high rate of co-occurring sexually transmitted infections means that sexual health clinics are likely to see additional monkeypox cases in the future. They call for additional resources to support services in managing this condition.
“Currently, the UK and several other countries are seeing a rapid increase in monkeypox cases among individuals attending sexual health clinics, with no apparent links to countries where the disease is endemic. Monkeypox is a novel diagnosis within the sexual health setting and our study, the first to publish on cases from this UK outbreak, will support future case finding and clinical care.” says Dr Nicolo Girometti, from the Chelsea & Westminster Hospital NHS Foundation Trust. 
The researchers collected data from monkeypox patients at four sexual health centres in London, UK. Confirmed cases were defined as individuals with laboratory-confirmed infection using a RT-PCR test. The researchers recorded data about the patient’s travel history, sexual history, and clinical symptoms. Individuals diagnosed with monkeypox were advised on isolation measures and regularly assessed subsequently via telephone welfare checks.
The 54 patients observed in this study represent 60% of the cases reported in the UK during the 12 day study period during May 2022. All except two of the patients in the cohort were not aware of having been in contact with a known case and none reported travel to sub-Saharan Africa, however many had recently visited other European countries. All patients identified as men who have sex with men and there was a median age of 41. 90% of the patients who responded to the questions on sexual activity (47/52) reported at least one new sexual partner during the three weeks prior to symptoms, and almost all (49/52) reported inconsistent condom use in this same time period. Over half of the patients (29/52) had more than five sexual partners in the 12 weeks prior to their monkeypox diagnosis.
The patients were all symptomatic and presented with skin lesions; 94% (49/52) of patients had at least one skin lesion on the genital or perianal skin. Mostly the patients had a mild illness and recovered whilst isolating at home, but five individuals required hospital admission due to pain or infection of the skin lesions. All improved and were discharged with a median of seven days of hospital admission.
“The commonly observed symptom of skin lesions in the anal and penile areas, and the fact that a quarter of the patients tested positive for gonorrhoea or chlamydia at the same time as the monkeypox infection, suggests that transmission of the monkeypox virus in this cohort is occurring from close skin-to-skin, for example in the context of sexual activity.” says Dr Ruth Byrne, from the Chelsea & Westminster Hospital NHS Foundation Trust. “However, this finding may be biased by the fact that we are sexual health providers and hence may not reflect transmission in the wider population.” 
Dr Byrne adds, “It is possible that at various stages of the infection monkeypox may mimic common STIs, such as herpes and syphilis, in its presentation. It’s important that sexual health clinicians and patients are aware of the symptoms of monkeypox as misdiagnosis of the infection may prevent the opportunity for appropriate intervention and prevention of onward transmission. Additional resources are urgently required to support services in managing this condition.” 
The study also observed important differences in the clinical features of this cohort compared to previous cases reported from earlier outbreaks in other countries. A lower proportion of patients in this cohort reported feeling weak and tired and/or having a fever than in studies on cases in previous outbreaks. Additionally, 18% (10/54) of patients in this cohort did not report any early symptoms before the onset of skin lesions.
Dr Girometti says, “Given the suggested route of infection via contact during sexual activity and the number of clinical findings differing from previous descriptions, we suggest that case definitions currently detailing symptoms such as acute illness with fever should be reviewed to best adapt to the current findings, as at least one in six of this cohort would have not met the current ‘probable case’ definition.” 
The authors acknowledge some limitations with this study, primarily its observational, retrospective nature. Additionally, the data is subject to selection biases as current guidance and health promotion materials prompt monkeypox testing in symptomatic individuals who self-define as MSM. The authors caution that their findings might not be representative of the overall outbreak. They caution that it is important to remain alert to the possibility of spread to other groups whilst still balancing targeted health promotion to groups disproportionately affected by the current outbreak.
NOTES TO EDITORS
This study was conducted by researchers from Chelsea & Westminster Hospital NHS Foundation Trust, Imperial College Healthcare NHS Trust, Central London Community Healthcare NHS Trust and Imperial College London.
 Quote direct from author and cannot be found in the text of the Article
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office firstname.lastname@example.org
The Lancet Infectious Diseases
Method of Research
Subject of Research
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis
Article Publication Date
LSPM has consulted for or received speaker fees from bioMerieux, DNAelectronics, Eumedica, Dairy Crest, Pfizer, Profile Pharma, Umovis Lab, Kent Pharma, Pulmocide, Sumiovant, and Shionogi, and received research grants from the National Institute for Health Research, CW+ charity, and LifeArc. NG has consulted for or received speaker fees from Viiv Healthcare. JH has received a research grant from the CW+ charity. DA has consulted for or received speaker fees from Viiv Healthcare and Theratechnologies. BM-P has consulted for or received speaker fees from MSD. NM has consulted for or received speaker fees from Pfizer and Shionogi. MBo has consulted for or received speaker fees from Viiv Healthcare, Gilead, GlaxoSmithKline, Pfizer, Cypla, Mylan, and Janssen. MBo has also received research grants from Gilead, Viiv Healthcare, Mylan, Novavax, Janssen, Valneva, Moderna, and Roche. RJ has consulted for or received speaker fees from Viiv Healthcare and Gilead. GW has consulted for or received speaker fees from Viiv Healthcare and Gilead. All other authors declare no competing interests.